Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results
Provided By GlobeNewswire
Last update: Mar 3, 2025
Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025
Read more at globenewswire.com
